- Home
- ATOS vs CGEN Comparison
ATOS vs CGEN Comparison
Compare ATOS & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- CGEN
- Stock Information
- Founded
- ATOS 2009
- CGEN 1993
- Country
- ATOS United States
- CGEN Israel
- Employees
- ATOS N/A
- CGEN N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATOS Health Care
- CGEN Health Care
- Exchange
- ATOS Nasdaq
- CGEN Nasdaq
- Market Cap
- ATOS 130.5M
- CGEN 125.3M
- IPO Year
- ATOS 2012
- CGEN 2000
- Fundamental
- Price
- ATOS $0.98
- CGEN $2.13
- Analyst Decision
- ATOS Strong Buy
- CGEN
- Analyst Count
- ATOS 3
- CGEN 0
- Target Price
- ATOS $6.25
- CGEN N/A
- AVG Volume (30 Days)
- ATOS 1.3M
- CGEN 440.6K
- Earning Date
- ATOS 11-11-2025
- CGEN 11-11-2025
- Dividend Yield
- ATOS N/A
- CGEN N/A
- EPS Growth
- ATOS N/A
- CGEN N/A
- EPS
- ATOS N/A
- CGEN N/A
- Revenue
- ATOS N/A
- CGEN $22,144,000.00
- Revenue This Year
- ATOS N/A
- CGEN N/A
- Revenue Next Year
- ATOS N/A
- CGEN $208.08
- P/E Ratio
- ATOS N/A
- CGEN N/A
- Revenue Growth
- ATOS N/A
- CGEN N/A
- 52 Week Low
- ATOS $0.55
- CGEN $1.13
- 52 Week High
- ATOS $1.66
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- ATOS 57.15
- CGEN 70.36
- Support Level
- ATOS $0.86
- CGEN $1.30
- Resistance Level
- ATOS $1.29
- CGEN $2.38
- Average True Range (ATR)
- ATOS 0.08
- CGEN 0.15
- MACD
- ATOS 0.01
- CGEN 0.07
- Stochastic Oscillator
- ATOS 38.23
- CGEN 76.24
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.